Cyxone announces forward looking drug development strategy with focus on Rabeximod in Rheumatoid Arthritis trial
Cyxone AB (CYXO), a clinical-stage company developing transformative therapies in the autoimmune area to improve patient outcomes, today provided a forward-looking strategy.Rabeximod in Rheumatoid Arthritis Rheumatoid arthritis (RA) is chronic disease, affecting more than 20 million patients globally, that require convenient rest-of-the-life treatment with as few side-effects and drug interactions as possible. There is still a large unmet need for new oral therapies with novel modes of action to give rheumatologists real alternatives to current therapies. Over 40% of patients don’t